Official List

Dalata Hotel Group PLC: Block Listing Application

Retrieved on: 
Wednesday, March 13, 2024

Dublin and London | 5 March 2024: Dalata Hotel Group plc (‘Dalata’ or the ‘Group’), the largest hotel operator in Ireland, with a growing presence in the United Kingdom and Continental Europe, today announces that a block listing application has been made, in aggregate, for 1,271,014 Ordinary Shares of €0.01 each in Dalata, pursuant to Dalata Hotel Group plc SAYE 2020 Scheme maturing.

Key Points: 
  • Dublin and London | 5 March 2024: Dalata Hotel Group plc (‘Dalata’ or the ‘Group’), the largest hotel operator in Ireland, with a growing presence in the United Kingdom and Continental Europe, today announces that a block listing application has been made, in aggregate, for 1,271,014 Ordinary Shares of €0.01 each in Dalata, pursuant to Dalata Hotel Group plc SAYE 2020 Scheme maturing.
  • The shares are to be admitted to (i) listing on the primary listing segment of the Official List of Euronext Dublin and to the standard listing segment of the Official List of the Financial Conduct Authority; and (ii) trading on Euronext Dublin's Main Securities Market and the London Stock Exchange's Main Market for listed securities.
  • Admission is expected to become effective at 8am on 7 March 2024.
  • When issued all of the above shares will be fully paid and will rank pari passu in all respects with the existing issued Ordinary Shares of the Company.

Wolters Kluwer successfully prices €600 million five-year Eurobond

Retrieved on: 
Monday, March 11, 2024

Alphen aan den Rijn – March 11, 2024 – Wolters Kluwer, a global leader of professional information, software solutions, and services, today announced that it has successfully priced a new €600 million five-year senior unsecured Eurobond.

Key Points: 
  • Alphen aan den Rijn – March 11, 2024 – Wolters Kluwer, a global leader of professional information, software solutions, and services, today announced that it has successfully priced a new €600 million five-year senior unsecured Eurobond.
  • The settlement date has been set for March 18, 2024.
  • The securities were placed with a broad range of institutional investors across Europe.
  • The bonds will be listed on the Official List of the Luxembourg Stock Exchange.

TUI AG:

Retrieved on: 
Tuesday, February 13, 2024

Following the passing of the UK Delisting Resolution, the Company will make applications to the FCA to cancel the admission of TUI AG shares to the Official List maintained by the FCA and to trading on the Main Market for listed securities of the London Stock Exchange (with trading occurring via depositary interests).

Key Points: 
  • Following the passing of the UK Delisting Resolution, the Company will make applications to the FCA to cancel the admission of TUI AG shares to the Official List maintained by the FCA and to trading on the Main Market for listed securities of the London Stock Exchange (with trading occurring via depositary interests).
  • It is anticipated that the last day of dealings of the TUI AG shares on the Main Market will be Friday, 21 June 2024.
  • Cancellation of the listing of the TUI AG shares on the Official List of the FCA is expected to take effect at 8:00 am on Monday, 24 June 2024.
  • The issuer is solely responsible for the content of this announcement.

Oxford Biomedica completes acquisition of ABL Europe

Retrieved on: 
Monday, January 29, 2024

Strengthens Oxford Biomedica’s position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple sites in EU, US and UK

Key Points: 
  • Strengthens Oxford Biomedica’s position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple sites in EU, US and UK
    Expands Oxford Biomedica’s ability to serve more clients, unlocking development capacity and increasing revenues
    Oxford, UK – 29 January 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces that, following the announcements on 20 September and 4 December 2023 , it has today completed the acquisition of ABL Europe SAS (“ABL Europe”) from Institut Mérieux SA ("Institut Mérieux").
  • The acquisition of ABL Europe, a pure-play European CDMO, strengthens Oxford Biomedica's position as a world-leading cell and gene therapy CDMO.
  • In addition, the acquisition increases Oxford Biomedica's capacity in process and analytical development and early-stage manufacturing across Adenovirus, Lentiviral vectors, AAVs and with this acquisition, MVA and Vaccinia.
  • This transaction opens up exciting growth opportunities for ABL Europe, that will significantly expand their offering to biopharma and biotech companies, and ultimately help more patients.”

TUI AG: PUBLICATION OF CIRCULAR AND NOTICE OF PROPOSED UK DELISTING RESOLUTION

Retrieved on: 
Thursday, January 4, 2024

If the UK delisting resolution is passed it is expected that the delisting would occur on 24 June 2024.

Key Points: 
  • If the UK delisting resolution is passed it is expected that the delisting would occur on 24 June 2024.
  • A circular with further details on the proposed UK delisting resolution has been approved by the UK Financial Conduct Authority and submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
  • It can also be viewed on the Company’s website at https://www.tuigroup.com/en-en/investors/agm.
  • The issuer is solely responsible for the content of this announcement.

Result of General Meeting, Result of Offer for Subscription and Total Voting Rights

Retrieved on: 
Saturday, December 30, 2023

As a result of the passing of the Resolution, the Company now has the requisite shareholder authority to complete the Placing, Subscription, Retail Offer and Offer for Subscription (the "Issue").

Key Points: 
  • As a result of the passing of the Resolution, the Company now has the requisite shareholder authority to complete the Placing, Subscription, Retail Offer and Offer for Subscription (the "Issue").
  • Accordingly, 21,261,548 New Ordinary Shares will be issued pursuant to the Issue at 270 pence each, raising gross proceeds of £57.4 million.
  • Admission is expected to become effective, and dealings to commence in the New Ordinary Shares, at 8.00 a.m. on 15 December 2023.
  • Following Admission, the Company will have 174,261,401 Ordinary Shares in issue with each share carrying the right to one vote.

Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO

Retrieved on: 
Monday, December 4, 2023

Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO

Key Points: 
  • Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO
    Provides Oxford Biomedica with multi viral vector CDMO capabilities – to be made available across the Company’s six manufacturing sites in EU, US and UK
    Oxford, UK – 4 December 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces that it has entered into a sale and purchase agreement (the “Agreement”) with TSGH SAS, a subsidiary of Institut Mérieux SA ("Institut Mérieux"), for the acquisition of ABL Europe SAS (“ABL Europe”) (the "Transaction").
  • The acquisition of ABL Europe will consolidate Oxford Biomedica's operations into a global pure-play CDMO in the cell and gene therapy space.
  • ABL Europe currently works on more than 10 cell and gene therapy programmes spanning disease areas including more than six different vector types.
  • Dr. Frank Mathias, Chief Executive Officer of Oxford Biomedica, commented: “The acquisition of ABL Europe strengthens Oxford Biomedica's operations into a global pure-play CDMO in the cell and gene therapy space.

Publication of the Prospectus and Circular

Retrieved on: 
Monday, December 25, 2023

Metro Bank Holdings PLC (LSE: MTRO LN)

Key Points: 
  • Metro Bank Holdings PLC (LSE: MTRO LN)
    NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN, OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.
  • The Prospectus contains a Notice of General Meeting, which will be held at One Southampton Row, London WC1B 5HA on 27 November at 11.30am.
  • The Prospectus has been approved by the FCA and, together with a form of proxy relating to voting at the General Meeting, is available on the Company’s website at: www.metrobankonline.co.uk/investor-relations .
  • Terms used in this announcement shall, unless the context otherwise requires, be as defined in the Prospectus.

Results of PrimaryBid Offer

Retrieved on: 
Thursday, December 21, 2023

Molten Ventures plc (LON: GROW, Euronext Dublin: GRW) announced on 27 November 2023 the launch of a fundraise comprising a placing (the "Placing") and subscription (the "Subscription") in conjunction with an offer via PrimaryBid (the "PrimaryBid Offer") (together the "Fundraise") alongside an Offer for Subscription (together with the Fundraise, the "Issue").

Key Points: 
  • Molten Ventures plc (LON: GROW, Euronext Dublin: GRW) announced on 27 November 2023 the launch of a fundraise comprising a placing (the "Placing") and subscription (the "Subscription") in conjunction with an offer via PrimaryBid (the "PrimaryBid Offer") (together the "Fundraise") alongside an Offer for Subscription (together with the Fundraise, the "Issue").
  • The Company is pleased to announce that the PrimaryBid Offer successfully completed and closed at 3.00 p.m. yesterday.
  • A total of 888,888 New Ordinary Shares have been subscribed for at a price of 270 pence per New Ordinary Share (the "Issue Price") pursuant to the PrimaryBid Offer.
  • Following the successful closing of the PrimaryBid Offer, the Company has raised gross proceeds of £57.4 million via the Fundraise.

Delisting and Cancellation of Trading From the London Stock Exchange

Retrieved on: 
Monday, November 27, 2023

Further to the announcement made on 27th October 2023, Marsh & McLennan Companies, Inc. (the "Company") announces that the listing of ordinary shares on the Standard Segment of the Official List of the Financial Conduct Authority and admission to trading on the Main Market for listed securities of the London Stock Exchange have now been cancelled with effect from 8:00 a.m. (GMT) today, 27th November 2023.

Key Points: 
  • Further to the announcement made on 27th October 2023, Marsh & McLennan Companies, Inc. (the "Company") announces that the listing of ordinary shares on the Standard Segment of the Official List of the Financial Conduct Authority and admission to trading on the Main Market for listed securities of the London Stock Exchange have now been cancelled with effect from 8:00 a.m. (GMT) today, 27th November 2023.
  • The Company continues to maintain its primary listing on the New York Stock Exchange.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20231127885063/en/